Inhibition of N-type calcium channels by phenoxyaniline and sulfonamide analogues†

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics
MedChemComm Pub Date : 2024-01-31 DOI:10.1039/D3MD00714F
Anjie S. Bispat, Fernanda C. Cardoso, Md. Mahadhi Hasan, Yashad Dongol, Ricki Wilcox, Richard J. Lewis, Peter J. Duggan and Kellie L. Tuck
{"title":"Inhibition of N-type calcium channels by phenoxyaniline and sulfonamide analogues†","authors":"Anjie S. Bispat, Fernanda C. Cardoso, Md. Mahadhi Hasan, Yashad Dongol, Ricki Wilcox, Richard J. Lewis, Peter J. Duggan and Kellie L. Tuck","doi":"10.1039/D3MD00714F","DOIUrl":null,"url":null,"abstract":"<p >Building on previous investigations, structural modifications to the neuronal calcium ion channel blocker MONIRO-1 and related compounds were conducted that included replacement of the amide linker with an aniline and isosteric sulfonamide moiety, and the previously used strategy of substitution of the guanidinium group with less hydrophilic amine functionalities. A comprehensive SAR study revealed a number of phenoxyaniline and sulfonamide compounds that were more potent or had similar potency for the Ca<small><sub>V</sub></small>2.2 and Ca<small><sub>V</sub></small>3.2 channel compared to MONIRO-1 when evaluated in a FLIPR-based intracellular calcium response assay. Cytotoxicity investigations indicated that the sulfonamide analogues were well tolerated by Cos-7 cells at dosages required to inhibit both calcium ion channels. The sulfonamide derivatives were the most promising Ca<small><sub>V</sub></small>2.2 inhibitors developed by us to date due, possessing high stability in plasma, low toxicity (estimated therapeutic index &gt; 10), favourable CNS MPO scores (4.0–4.4) and high potency and selectivity, thereby, making this class of compounds suitable candidates for future <em>in vivo</em> studies.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":null,"pages":null},"PeriodicalIF":3.5970,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2024/md/d3md00714f?page=search","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/md/d3md00714f","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Building on previous investigations, structural modifications to the neuronal calcium ion channel blocker MONIRO-1 and related compounds were conducted that included replacement of the amide linker with an aniline and isosteric sulfonamide moiety, and the previously used strategy of substitution of the guanidinium group with less hydrophilic amine functionalities. A comprehensive SAR study revealed a number of phenoxyaniline and sulfonamide compounds that were more potent or had similar potency for the CaV2.2 and CaV3.2 channel compared to MONIRO-1 when evaluated in a FLIPR-based intracellular calcium response assay. Cytotoxicity investigations indicated that the sulfonamide analogues were well tolerated by Cos-7 cells at dosages required to inhibit both calcium ion channels. The sulfonamide derivatives were the most promising CaV2.2 inhibitors developed by us to date due, possessing high stability in plasma, low toxicity (estimated therapeutic index > 10), favourable CNS MPO scores (4.0–4.4) and high potency and selectivity, thereby, making this class of compounds suitable candidates for future in vivo studies.

Abstract Image

Abstract Image

苯氧基苯胺和磺酰胺类似物对 N 型钙通道的抑制作用
在先前研究的基础上,我们对神经元钙离子通道阻断剂 MONIRO-1 和相关化合物进行了结构改造,包括用苯胺和同位磺酰胺分子取代酰胺连接体,以及用亲水性较弱的胺官能团取代胍基等先前使用过的策略。在基于 FLIPR 的细胞内钙响应分析中进行评估时,一项全面的 SAR 研究发现,与 MONIRO-1 相比,一些苯氧基苯胺和磺酰胺化合物对 CaV2.2 和 CaV3.2 通道的作用更强或作用相似。细胞毒性研究表明,在抑制两种钙离子通道所需的剂量下,磺酰胺类似物对 Cos-7 细胞的耐受性良好。磺酰胺衍生物是我们迄今为止开发的最有前途的 CaV2.2 抑制剂,因为它们在血浆中具有高稳定性、低毒性(估计治疗指数为 10)、良好的中枢神经系统 MPO 评分(4.0-4.4)以及高效力和选择性,从而使这类化合物成为未来体内研究的合适候选化合物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信